Immediate Impact
34 standout
Citing Papers
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of Daniel Roessler being referenced
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
2022
Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Daniel Roessler | 100 | 61 | 64 | 9 | 199 | |
| Zhangping He | 21 | 29 | 27 | 16 | 194 | |
| Anita Rack | 14 | 21 | 63 | 8 | 298 | |
| Daniel Shu | 44 | 96 | 25 | 14 | 283 | |
| Elizabeth Atkins | 78 | 18 | 60 | 12 | 290 | |
| Yen‐Wei Chien | 119 | 21 | 15 | 8 | 277 | |
| Mary Carsillo | 11 | 10 | 50 | 15 | 231 | |
| M.C. Saint Paul | 167 | 33 | 21 | 8 | 291 | |
| Luis Gil‐Grande | 77 | 13 | 51 | 10 | 278 | |
| Ilka Rebhan | 118 | 40 | 35 | 7 | 251 | |
| Mariarosaria Del Sorbo | 36 | 15 | 77 | 6 | 208 |
All Works
Login with ORCID to disown or claim papers
Loading papers...